PMID- 19815243
OWN - NLM
STAT- MEDLINE
DCOM- 20100315
LR  - 20181201
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
VI  - 59
IP  - 3
DP  - 2010 Mar
TI  - Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin 
      levels in patients with type 2 diabetes mellitus.
PG  - 373-9
LID - 10.1016/j.metabol.2009.08.005 [doi]
AB  - Visfatin, ghrelin, and apelin are the most recently identified adipocytokines; 
      but their response to insulin-sensitizing agents is poorly clarified. We aimed to 
      assess the differential effects of either rosiglitazone or metformin monotherapy 
      on the aforementioned adipocytokines in patients with type 2 diabetes mellitus 
      (T2DM). One hundred T2DM patients (30 men, 70 women), with poor glycemic control 
      (glycosylated hemoglobin >6.5%) while taking 850 mg of metformin daily, were 
      enrolled. All participants were randomized to receive either adjunctive therapy 
      with rosiglitazone (8 mg/d, n = 50) or the maximum dose (2550 mg/d) of metformin 
      (MET group, n = 50). Anthropometric parameters, glycemic and lipid profile, 
      high-sensitivity CRP (hs-CRP), insulin resistance (homeostasis model assessment 
      of insulin resistance index [HOMA-IR]), visfatin, ghrelin, and apelin were 
      assessed at baseline and after 14 weeks of therapy. Both rosiglitazone and 
      metformin led to similar, significant improvement in glycemic profile and apelin 
      levels, whereas lipid parameters, fat mass, and visfatin remained almost 
      unaffected (P > .05). Insulin resistance was significantly attenuated in both 
      groups, but to a lesser degree in the MET group (P = .045). Rosiglitazone-treated 
      patients experienced a significant decrease in hs-CRP and systolic blood pressure 
      compared with baseline values and those of the MET group (P < .05). Besides, 
      rosiglitazone treatment considerably increased plasma ghrelin (3.74 +/- 1.52 
      ng/mL) in comparison with either baseline (P = .034) or metformin monotherapy 
      values (-2.23 +/- 1.87 ng/mL, P = .008). On the other hand, the MET group, rather 
      than the rosiglitazone group, had decreased body mass index (-0.79 +/- 0.47 vs 
      0.56 kg/m(2), P = .009). The aforementioned changes in apelin and ghrelin were 
      independently associated with HOMA-IR changes. Both rosiglitazone and metformin 
      favorably changed glycemic indexes and apelin levels. The addition of 
      rosiglitazone seemed to confer greater benefits in ghrelin, hs-CRP, systolic 
      blood pressure, and HOMA-IR regulation than metformin monotherapy. Although these 
      results reflect improvement in cardiovascular risk profile, the overall clinical 
      importance of insulin sensitizers must be further assessed.
CI  - (c) 2010 Elsevier Inc. All rights reserved.
FAU - Kadoglou, Nikolaos P E
AU  - Kadoglou NP
AD  - First Department of Internal Medicine, Hippokratio General Hospital of 
      Thessaloniki, Greece. nikoskad@yahoo.com
FAU - Tsanikidis, Hercules
AU  - Tsanikidis H
FAU - Kapelouzou, Alkistis
AU  - Kapelouzou A
FAU - Vrabas, Ioannis
AU  - Vrabas I
FAU - Vitta, Ioulia
AU  - Vitta I
FAU - Karayannacos, Panayotis E
AU  - Karayannacos PE
FAU - Liapis, Christos D
AU  - Liapis CD
FAU - Sailer, Nikolaos
AU  - Sailer N
LA  - eng
SI  - ClinicalTrials.gov/NCT00373178
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20091007
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (APLN protein, human)
RN  - 0 (Adipokines)
RN  - 0 (Apelin)
RN  - 0 (Ghrelin)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
SB  - IM
MH  - Adipokines/blood
MH  - Aged
MH  - Apelin
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Ghrelin/*blood
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Intercellular Signaling Peptides and Proteins/*blood
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Nicotinamide Phosphoribosyltransferase/*blood
MH  - Rosiglitazone
MH  - Thiazolidinediones/*therapeutic use
MH  - Waist-Hip Ratio
EDAT- 2009/10/10 06:00
MHDA- 2010/03/17 06:00
CRDT- 2009/10/10 06:00
PHST- 2009/03/17 00:00 [received]
PHST- 2009/07/29 00:00 [revised]
PHST- 2009/08/07 00:00 [accepted]
PHST- 2009/10/10 06:00 [entrez]
PHST- 2009/10/10 06:00 [pubmed]
PHST- 2010/03/17 06:00 [medline]
AID - S0026-0495(09)00329-1 [pii]
AID - 10.1016/j.metabol.2009.08.005 [doi]
PST - ppublish
SO  - Metabolism. 2010 Mar;59(3):373-9. doi: 10.1016/j.metabol.2009.08.005. Epub 2009 
      Oct 7.